Predictors of Acute Renal Injury Study (PARIS) among HIV-positive individuals: design and methods. by Corona-Villalobos, Celia P et al.
UCSF
UC San Francisco Previously Published Works
Title
Predictors of Acute Renal Injury Study (PARIS) among HIV-positive individuals: design and 
methods.
Permalink
https://escholarship.org/uc/item/43v982c2
Journal
BMC nephrology, 18(1)
ISSN
1471-2369
Authors
Corona-Villalobos, Celia P
Shlipak, Michael G
Tin, Adrienne
et al.
Publication Date
2017-09-07
DOI
10.1186/s12882-017-0696-1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
STUDY PROTOCOL Open Access
Predictors of Acute Renal Injury Study
(PARIS) among HIV-positive individuals:
design and methods
Celia P. Corona-Villalobos1, Michael G. Shlipak2, Adrienne Tin3, Chirag Parikh4, Richard D. Moore3,5, Eric Vittinghoff2,
Jose Manuel Monroy-Trujillo1, Mohamed G. Atta1 and Michelle M. Estrella2*
Abstract
Background: Acute kidney injury (AKI), which is common among HIV-positive individuals, may contribute to the
excess burden of chronic kidney disease (CKD) in this patient population; however, conventional clinical methods to
detect AKI do not capture kidney injury sufficiently early to prevent irreversible damage. Further, large observational
and interventional studies of AKI generally exclude HIV-positive persons in spite of their disproportionate risk.
Methods: The Predictors of Acute Renal Injury Study (PARIS) is a prospective observational cohort study among
HIV-positive individuals established to determine the ability of candidate kidney injury biomarkers to predict future
hospitalized clinical AKI, to characterize hospitalized subclinical AKI, and to discern the risk of progressive kidney
disease following subclinical and clinical AKI. Among the candidate kidney injury markers, we will select the most
promising to translate into a clinically viable, multiplex panel of urinary biomarkers which we will integrate with
clinical factors to develop a model prognostic of risks for AKI and subsequent kidney function decline. This study
has a targeted enrollment of 2000 participants. The overall follow-up of participants consists of two phases: 1) a 5-
year active follow-up phase which involves serial evaluations at enrollment, annual clinic visits, and among
participants who are hospitalized during this period, an evaluation at index hospitalization and 3 and 12 months
post-hospitalization; and 2) a subsequent passive follow-up phase for the duration that the participant receives
medical care at The Johns Hopkins Hospital.
Discussions: This study will serve as an important resource for future studies of AKI by establishing a repository
with both ambulatory and inpatient biospecimens, a resource that is currently lacking in existing HIV clinical
cohorts and studies of AKI. Upon completion of this study, the resulting prognostic model which will incorporate
results from the multiplex HIV-AKI Risk Pane could serve as a pharmacodynamic endpoint for early phase
therapeutic candidates for AKI.
Background
In the modern era of effective antiretroviral therapy,
HIV-positive individuals remain at increased risk of de-
veloping chronic kidney disease (CKD) and progressing
to end-stage renal disease (ESRD). This risk remains
substantial even among persons who achieve adequate
viral suppression and is not fully explained by traditional
risk factors for CKD. Acute kidney injury (AKI), which
affects approximately 1 in 6 hospitalized HIV-positive
patients, may be contributing to this persistent CKD
burden [1].
Studies in the general population indicate that clinical
repercussions of AKI persist beyond hospitalizations,
even as long as 10 years after AKI has occurred [2].
Among HIV-positive patients who survive at least
90 days after their hospitalization, AKI severity has been
associated with a 2- to 4-fold increased risk of heart fail-
ure, a 1.3- to 2-fold increased risk of cardiovascular dis-
ease, a 3.8- to 20-fold increased risk of ESRD and up to
a 1.7-fold increased risk of all-cause mortality [1]. Even
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among patients who return to their baseline serum
creatinine, the risk of progression to ESRD and death
remain significantly elevated. These findings suggest that
HIV-positive individuals may sustain extensive kidney
injury that is not fully captured by currently available
clinical methods, such as serum creatinine, to detect
AKI and measure its severity.
Although the current national guidelines define AKI
based on absolute and relative increases in serum cre-
atinine and/ or declines in urine output, these parame-
ters may not be altered until over half of kidney function
has been lost. Given these limitations, many individuals
may sustain critical kidney damage despite serum cre-
atinine levels and urine output remaining unchanged.
This condition has been described as “subclinical AKI”
[3] characterized by elevations in urine biomarkers of
kidney injury, such as kidney injury marker-1 (KIM-1)
and preserved serum creatinine levels. Recently, the
Translational Research Investigating Biomarker
Endpoints in AKI (TRIBE-AKI) Consortium has shown
that among patients with clinical AKI following major
cardiac surgery [4], the highest compared to the lowest
tertiles of urine neutrophil gelatinase-associated lipocalin
(NGAL), IL-18 and KIM-1 were each independently
associated with a more than doubling of mortality risk
after hospital discharge [5]. Patients with subclinical AKI
(defined by urine IL-18 and KIM-1 elevations in the
absence of serum creatinine elevations) also had signifi-
cantly higher 3-year mortality risk after hospitalization.
Urine biomarkers, which are sensitive and specific for
renal tubulointerstitial injury, inflammation and fibrosis,
are growing in number and reshaping the concept of
AKI into a continuum of risk [6] which spans from “at-
risk” populations, to subclinical AKI to clinically overt
AKI. However, the current understanding of hospitalized
AKI has primarily relied on serum creatinine levels at
hospital admission. Furthermore, the prognostic and
predictive performance of novel urine biomarkers of
kidney injury has largely been assessed without baseline
ambulatory levels due to the lack of stored blood and
urine samples prior to AKI events in most if not all
studies [7–10]. Most importantly, despite the burden of
AKI in the HIV-positive population and recent advances
in kidney injury biomarkers, very few studies of AKI
have comprehensively focused on this high-risk patient
population. Consequently, there remains a lack of strat-
egies to identify HIV-positive persons at highest risk of
AKI and its related adverse outcomes. We hypothesize
that higher ambulatory levels of urine biomarkers denote
ongoing subclinical kidney injury that portends higher
risk of subsequent hospitalization and clinical AKI. We
further postulate that higher urine biomarker levels of
kidney injury during hospitalization are predictive of
longitudinal kidney function decline.
To address these unmet clinical needs and ultim-
ately mitigate the disproportionate risk of AKI and its
consequences in the HIV-positive population, we
established the Predictors of Acute Renal Injury Study
(PARIS) in 2015. Through support from the National
Institute of Diabetes, Digestive and Kidney Diseases
(R01-DK-103574) and additional resources from the
Johns Hopkins Institute of Clinical and Translational
Research (ICTR) and Center for AIDS Research
(1P30-AI-094189), this study will determine the ability
of candidate kidney injury biomarkers to predict hos-
pitalized clinical AKI, to characterize subclinical AKI,
and to discern the risk of progressive kidney disease
following subclinical and clinical AKI among a pro-
spective cohort of HIV-positive individuals. PARIS
specifically aims to:
 Establish a prospective cohort of HIV-positive indi-
viduals treated in a large academic HIV practice, the
Johns Hopkins Hospital HIV Clinic, with detailed
clinical data and biological samples collected in both
the outpatient and inpatient settings
 Determine the association of ambulatory kidney
damage with incident hospitalized clinical AKI and
progressive kidney disease after AKI
 Investigate the prevalence of subclinical and clinical
AKI among hospitalized HIV-positive individuals
and their associations with progressive kidney
disease after hospitalization
 Develop a prognostic model that integrates a
multiplex panel of complementary urine biomarkers
and clinical variables that will distinguish risk for
incident AKI and subsequent progressive kidney
disease and that will be feasible to implement in
clinical practice
The culmination of this work will greatly enhance our
understanding of subclinical and clinical AKI and their
contribution to adverse health outcomes among HIV-
positive persons. In addition, it will yield a prognostic
model that incorporates a clinically applicable multiplex
HIV-AKI Risk Panel which could then be tested as a
screening tool in clinical trials of AKI management as
well as a pharmacodynamic endpoint for early phase
therapeutic candidates for AKI [11].
Methods
Overall study design
PARIS is a collaboration among investigators at the
University of California, San Francisco, San Francisco
Veterans Affairs Medical Center, Yale University and
Johns Hopkins School of Medicine. This prospective
observational cohort study enrolls and follows all eli-
gible HIV-positive individuals who are receiving care
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through the Johns Hopkins Hospital HIV Clinic in
Baltimore, Maryland, USA. To augment data collection,
PARIS will leverage the established infrastructure of the
Johns Hopkins HIV Clinical Cohort (JHHCC), an NIH-
sponsored open cohort established in 1990 to provide lon-
gitudinal data on HIV-positive patients cared for at the
Moore Clinic [12]. The JHHCC enrolls new patients as
they initiate longitudinal HIV care at the HIV Clinic, with
a consent rate of over 98%. The Institutional Review
Boards at the University of California, San Francisco, the
San Francisco Veterans Affairs Medical Center, Yale
University, and the Johns Hopkins School of Medicine
approved the study.
The overall follow-up of participants consists of two
phases: 1) a 5-year active follow-up phase; and 2) a
subsequent passive follow-up phase for the duration
that the participant receives medical care within the
Johns Hopkins Health System. The active follow-up
phase enables investigators to prospectively collect
data and biospecimens from the participants at sched-
uled study visits and during hospitalized clinical
events of interest. This phase is comprised of a base-
line visit and 3 years of annual ambulatory follow-up
visits in the Johns Hopkins Outpatient Clinical
Research Unit among all participants for question-
naires and biospecimen collection, up to 4 years from
enrollment for capture of hospitalization and AKI
events among all participants, and an additional year
of follow-up among those who are hospitalized. The
subsequent passive follow-up phase allows for on-
going evaluation of long-term outcomes, such as
cardiovascular disease events, ESRD, and mortality.
This phase entails ongoing review of the participants’
health records as well as linkage to outcomes
registries, such as the U.S. Renal Data System and
the National Death Index (Fig. 1).
While biospecimens are collected on all partici-
pants, a nested case-cohort design [13] will be
employed to evaluate the association between ambula-
tory levels of urine biomarkers with incident clinical
AKI. In the nested case-cohort, annual ambulatory
biomarkers will be measured only among incident
cases of hospitalized clinical AKI and a random sam-
ple of the overall population (Fig. 2). This approach
enables estimation of risks without having to measure
biomarkers repeatedly on all participants and yields
unbiased estimates of the population prevalence of
AKI risk factors [13]. It also provides a subcohort
representative of the overall population that allows
study of other outcomes. To investigate the preva-
lence of subclinical and clinical AKI among hospital-
ized HIV-positive individuals and their associations
with progressive kidney disease after hospitalization, a
traditional cohort design will be used.
Cohort participants
Source population
The PARIS Study enrolls among HIV-positive patients
who receive ambulatory care at the Johns Hopkins HIV
Clinic. This clinic represents the largest program for HIV
care within the state of Maryland, USA, currently with
over 2800 HIV-positive patients and approximately 20,000
patient-visits annually. It provides multidisciplinary care
tailored to the needs of patients with HIV. Based on data
captured by the JHHCC, approximately 77% and 3% of
the patients self-report as African American and Latino,
respectively, and 35% are women. The current median age
is 48 years (interquartile range [IQR]: 40 to 54 years).
Fig. 1 Phases of Follow-up in the PARIS Cohort. The active follow-up
phase consists of 3 years of annual ambulatory follow-up visits for
questionnaires and biospecimen collection and up to 4 years from
enrollment for capture of hospitalization and AKI events among all
participants, and an additional year of follow-up among those who
are hospitalized. The subsequent passive follow-up phase allows for
ongoing evaluation of long-term outcomes for the duration that the
participant receives medical care within the Johns Hopkins Health
System. AKI: Acute Kidney Injury; CRU: Clinical Research Unit, USRDS:
United States Renal Data System, DI: Death Index
Fig. 2 Nested Case-Cohort Design for Annual Ambulatory Biomarker
Measurements. In the nested case-cohort design, annual ambulatory
biomarkers will be measured only among incident cases of hospitalized
clinical AKI and a random subsample of the overall cohort. AKI: Acute
Kidney Injury; t: Time
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Approximately 27% report homosexual activity while 33%
report intravenous drug use. Thirty-seven percent are co-
infected with the hepatitis C virus. At enrollment, the me-
dian estimated glomerular filtration rate (eGFR) is
105.0 mL/min/1.73 m2 (IQR: 87.0–123.0). More than 90%
of ambulatory and inpatient care for Moore Clinic patients
is delivered within The Johns Hopkins Hospital. In
addition, 98.4% of patients who receive care in the Moore
Clinic are also enrolled in the JHHCC.
Participant selection
To participate in PARIS, a patient must meet the follow-
ing inclusion criteria: 1) HIV-positive; 2) age 18 years or
older; 3) English-speaking; 4) actively followed clinically
at the Johns Hopkins HIV Clinic; and 5) has not experi-
enced AKI within the preceding 6 months. Patients who
have experienced clinical AKI within the preceding
6 months; reside in a hospice, skilled nursing facility or
prison; have health conditions that interfere with study
participation (e.g. significant cognitive impairment or ac-
tive psychotic illness); plan to move out of state within
the next year; are receiving chronic renal replacement
therapy, have an eGFR of <15 mL/min/1.73m2; have had
a previous solid organ transplant; or self-report current
pregnancy are excluded. To ascertain potential partici-
pants’ eligibility on these criteria, we conduct patient in-
terviews and review electronic health records. The
participant’s most recent value recorded in the electronic
health record within the preceding year is regarded as
the baseline serum creatinine. The baseline eGFR is cal-
culated using either the abbreviated Modification of Diet
in Renal Disease (MDRD) [14] as used within the Johns
Hopkins Medicine Pathology Department or the CKD-
Epidemiology Collaboration (CKD-EPI) equation [15] as
used by Quest Diagnostics (Quest Diagnostics, Inc.,
Madison, MJ, USA) and LabCorp (LabCorp Diagnostics,
Burlington, NC, USA). All clinical serum creatinine re-
sults are measured using an assay traceable to an isotope
dilution mass spectrometry.
Screening and enrollment of participants
We aim to enroll 2000 HIV-positive individuals over a
period of 2.5 years. Participants are recruited using vari-
ous approaches, including use of study bulletins and
brochures, provider referrals, and study informational
“hotline”. All HIV-positive individuals receiving ambula-
tory care at the Moore Clinic are screened for enroll-
ment at the time a patient attends an ambulatory clinic
visit and provides permission to be approached by inves-
tigators, at the time a patient contacts study personnel
directly, or at a separate screening visit at the Johns
Hopkins Outpatient Clinical Research Unit.
Retention strategies
Retention of participants is critical to the successful
completion of the study. Based on the data from the
JHHCC [12], we anticipate that approximately 5% of
participants will be lost to follow-up annually. To
minimize participant drop-out, we have implemented
several retention strategies. First, we have developed a
study tracking system that maintains up-to-date contact
information for the participant, secondary contact per-
sons, and clinical providers. This tracking system also in-
cludes detailed information on scheduled and upcoming
visit dates. Second, we ensure that participants are
reminded of upcoming scheduled study visits via written
letters and telephone calls. Third, participants receive
compensation for each of the study visits they complete.
In addition, the study links to registries, such as the U.S.
Renal Data System and the National Death Index to
ascertain outcomes on renal replacement therapy or
kidney transplantation and vital status, respectively. For
those participants also enrolled in the JHHCC, we will
link with the JHHCC database for follow-up on clinical
data. As part of our quality assurance and insurance
practices, we monitor completion rates of participant
contacts and study visits.
Timeline of study visits during active follow-up
Individuals enrolled in the study will participate in a
series of study visits for collection of data and biospeci-
mens which are summarized in Table 1. After the base-
line study visit, participants will return for annual
ambulatory follow-up visits for the first 3 years of the
study or until their first hospital admission during
follow-up. Those who are hospitalized and who develop
hospitalized clinical AKI will be identified in real-time
by using computer-based programs linked to the Johns
Hopkins electronic health records. Participants who are
hospitalized undergo additional inpatient study visits
within 24 h, 48 h, and 72 h of hospitalization, at the time
of AKI diagnosis (if applicable), and at the time of hos-
pital discharge. Following hospitalization, these individ-
uals participate in two additional ambulatory in-person
study visits at 3 and 12 months post-discharge and one
telephone contact at 6 months post-discharge.
Data collection procedures
Data are collected through study visits, participants’
electronic health records, JHHCC database, and national
registries (Table 2). During ambulatory study visits,
detailed data are collected on participants’ contact
information, health provider information, socio-
demographics, behavioral history, medical and family his-
tory and current as well as prior medication use, including
antiretroviral therapy and over-the counter medications.
In addition, participants undergo standardized resting
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blood pressure and anthropometric measurements (height
and weight), short assessments of health literacy (SAHL-
E) [16] and neurocognitive assessments using Part A and
B Trail Making Tests [17].
In order to account for potential confounders, detailed
data on ambulatory clinic visits and hospitalizations are
also collected through the participants’ electronic health
records (Table 3). These data include pre-existing kidney
disease, other co-morbid conditions, and hospitalization-
related factors. Specifically, the presence of pre-existing
chronic kidney disease based on albuminuria, protein-
uria and/ or eGFR is ascertained. Moreover, as hyperten-
sion and degree of blood pressure control are relevant to
AKI risk and eGFR decline [18, 19], we assess for base-
line hypertension and longitudinal blood pressures.
Comprehensive, accurate ascertainment of medication
use is critical for drug-related impact on AKI risk and
subsequent kidney function decline. Therefore, we
gather detailed data on use of antiretroviral medica-
tions, non-steroidal anti-inflammatory drugs (NSAIDs),
antibiotics, and renin-angiotensin system (RAS)-antag-
onists (e.g. ACE-inhibitors). In addition, we obtain
hospitalization-related data, including reason for ad-
mission, discharge diagnoses, procedures and if applic-
able, clinical AKI severity.
We will enrich the PARIS data collection through an-
nual linkage with the JHHCC database for participants
who are also enrolled in the JHHCC. Similar to PARIS,
data are collected through patient interviews, electronic
patient records, other electronic sources of ambulatory/
inpatient services, and records from other facilities.
These data sources are routinely captured per clinical
protocol and include hospitalizations within the Johns
Hopkins Health System and other facilities in Baltimore,
Table 1 Overall study timeline and corresponding primary exposures and outcomes of interest
JHHCC Johns Hopkins HIV Clinical Cohort, CRU Clinical Research Unit, GFR Glomerular Filtration Rate, AKI Acute Kidney Injury, CKD Chronic Kidney Injury
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MD, USA and visits to any of the outpatient primary
care and specialty services and emergency department.
Clinical data collected by the JHHCC include compre-
hensive data on clinical chemistry laboratory, radio-
logical and pathological results, pharmacy use (including
prescriptions and refills), and healthcare utilization. Of
note, more than 95% of laboratory data are collected
electronically through direct linkage to Johns Hopkins
databases and outside laboratories. The JHHCC also
links to vital statistics databases and the USRDS.
Biospecimen collection and repository
As part of PARIS procedures, we collect biospecimens
during the baseline and annual ambulatory study visits,
hospitalizations, and post-hospitalization study visits as
summarized in Table 2. Blood specimens are processed
for serum, plasma and whole blood. We also utilize spe-
cialized collection and storage tubes for preservation of
RNA. As handling and storage of urine specimens influ-
ence measurement of urine biomarkers [20], urine
specimens are immediately refrigerated at 4 °C until
laboratory processing within 2 h of collection. Urine
specimens are subsequently processed to yield urine pel-
lets, urine supernatant and uncentrifuged urine samples.
All biospecimens are aliquoted and stored at −80 °C. For
quality assurance and insurance, the date and timing of
biospecimen collections and processing are recorded
and monitored.
Table 3 Potential confounders of the association between biomarkers and outcomes
Potential confounders Outcomes
Incident hospitalized AKI Subsequent kidney function
Socio demographic Age Baseline Baseline
Race Baseline Baseline
Gender Baseline Baseline
Injection drug use Baseline Time-varying post-discharge
Baseline CKD Albuminuria Baseline Baseline
eGFR Baseline Baseline
Chronic Co-morbid
Conditions
HCV co-infection Baseline history Baseline history
Diabetes Mellitus Baseline history Baseline history
Hypertension Baseline history, ambulatory systolic
& diastolic blood pressure
Baseline history, ambulatory systolic
& diastolic blood pressure
Cardiovascular disease Baseline history Baseline history
HIV Disease Stage AIDS history Time-updated absorbent state Time-updated absorbent state
CD4+ cell count Time-varying Time-varying
HIV-1 RNA level Time-varying Time-varying
Medication Exposure Antiretroviral drugs (evaluated as
HAART, ART classes and individual
drugs)
Cumulative Cumulative post-discharge
NSAIDs Cumulative Cumulative post-discharge
RAS-antagonist Cumulative Cumulative post-discharge
Hospitalization-
related factors
Antibiotic (by class) Cumulative In-patient exposure
IV contrast — In-patient exposure
AKI — AKI stage; peak serum creatinine
Intensive care unit stay — In-patient exposure
Duration of hospitalization —
Primary discharge diagnosis — Categorized: Cardiovascular, infectious,
respiratory, gastrointestinal, cancer, other
Anthropometric
measurements
Weight Baseline Baseline
Height Baseline Baseline
Waist circumference Baseline Baseline
Hip circumference Baseline Baseline
AKI Acute Kidney Injury, CKD Chronic Kidney Disease, eGFR estimated Glomerular Filtration Rate; HCV Hepatitis C Virus, AIDS acquired Immune Deficiency
Syndrome, CD4 Cluster of Differentiation 4; Human Immunodeficiency Virus; HAART Highly Active Antiretroviral Therapy, ART Antiretroviral Therapy; HIV: NSAIDs
Nonsteroidal Anti-inflammatory Drugs, RAS Renin-Angiotensin System, IV Intra-Venous
Corona-Villalobos et al. BMC Nephrology  (2017) 18:289 Page 8 of 12
Laboratory measurements
Method of serum creatinine measurement and GFR estimation
Standardized serum creatinine will be measured locally
using an enzymatic method traceable to IDMS. This
method has less measurement variability compared alka-
line picrate assays for creatinine [21]. The serum
creatinine-based CKD-EPI equation [15] will be used to
estimate GFR.
Methods for urine biomarker measurement
To assess hospitalized AKI accurately, baseline assess-
ment of kidney function and injury are essential. To de-
termine the association of ambulatory kidney damage
with incident hospitalized clinical AKI and progressive
kidney disease after AKI and to investigate the preva-
lence of subclinical and clinical AKI among hospitalized
HIV-positive individuals and their associations with pro-
gressive kidney disease after hospitalization, individual
urine biomarkers of kidney injury will be measured
using commercially available enzyme-linked immuno-
sorbent assay (ELISA).
To develop a prognostic panel of complementary urine
biomarkers that could be feasibly integrated into clinical
practice, we will utilize results from single biomarkers to
inform selection of an array of urine biomarkers which
we will develop into a multiplex HIV-AKI Risk Panel
based on the solid array-based method of Meso Scale
Discovery array (Meso Scale Diagnostics, LLC., Rock-
ville, MD, USA). Compared to readers for ELISAs, the
electrochemiluminescence reader (MESO SECTOR) is
several-fold more sensitive and covers a much broader
range of biomarker concentration [22, 23]. Moreover,
the electrochemiluminescence reader yields results more
rapidly compared to those for ELISAs.
Outcomes of interest
The outcomes of interest include hospitalized clinical
AKI, hospitalized subclinical AKI, the composite of renal
non-recovery and all-cause mortality at 3 months post-
discharge, and kidney disease progression after 3-
months post-discharge. Hospitalized clinical AKI and its
severity will be defined using serum creatinine thresh-
olds endorsed by the Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines on AKI [24] (Table 4).
Hospitalized subclinical AKI is defined as an increase in
urine biomarker level of 25% or greater from the most
recent ambulatory level, among those who do not meet
the criteria for clinical AKI. We will also evaluate alter-
native definitions, defining subclinical AKI among those
who do not meet criteria for clinical AKI as: 1) a urine
biomarker level above the top quartile of those without
AKI; or 2) ≥4 biomarkers with levels ≥25% above the
most recent ambulatory levels. Because surveillance for
subclinical AKI is completely novel in this setting, we
will pursue an iterative analytical approach.
For the composite outcome of renal non-recovery at
3 months and all-cause mortality among participants
who are hospitalized and develop clinical AKI, renal
non-recovery is defined as >25% decrease in eGFR at
3 months post-discharge from the most recent ambula-
tory level. Deaths are ascertained through abstraction of
medical records, including those from outside institu-
tions and death certificates. The vital status of partici-
pants who have not presented to the PARIS study visits
or HIV Clinic and were last known to be living is
checked annually through various vital statistic sources,
including the National Death Index, Maryland Vital
Records, and Social Security Death Files. Outcomes
assessment at 3 months following hospitalization has
been recognized as a potentially meaningful time point
by the National Institute of Diabetes and Digestive and
Kidney Diseases and the Food and Drug Administration
for the assessment of urine biomarkers [25].
Among hospitalized participants with eGFRs
≥15 ml/min/1.73 m2 at 3 months post-discharge, the
outcome of kidney disease progression will be evalu-
ated. Post-discharge eGFR will be assessed using re-
peated estimates of GFR at 3 months, 12 months and
up to 4 years of active follow-up. For eGFRs beyond
12 months, we will use the eGFR closest to the
3 months post-discharge date (i.e. annualized eGFR).
This approach allows unbiased ascertainment of post-
discharge eGFR; however, we will also conduct sensi-
tivity analyses in which we use all available eGFRs
after 3 months post-discharge. Kidney disease pro-
gression will be defined by the development of >30%
decline in eGFR or progression to stage 5 CKD
(eGFR <15 mL/min/1.73 m2, or ESRD) during longi-
tudinal follow-up [26]. ESRD events will be ascer-
tained by medical record abstraction and annual
linkage to the U.S. Renal Data System, and JHHCC
database.
Sample size and power estimations
To determine the cohort sample size, we assumed 80%
power and a two-tailed alpha of 0.05. Where possible,
Table 4 Acute kidney injury definition and staging based on
serum creatinine
Definition • Increase =0.3 mg/dl within 48 h OR
• =1.5× baseline which is known OR
• Presumed to have occurred within the prior 7 days
Stage
1 • 1.5–1.9× baseline OR =0.3 mg/dl increase
2 • 2–2.9× baseline
3 • Increase to =4 mg/dl OR
• Initiation of renal replacement therapy
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the standard deviations (SD) for biomarkers were taken
from published literature or observations in TRIBE- AKI
Consortium [4]. We estimated the effect size for the
nested case-cohort analyses by simulations using the
Nested Cohort package in R (R Foundation for Statistical
Computing). Other calculations were conducted using
SAS 9.3 (SAS Institute, Inc.). We estimated the number
of events based on observations in the JHHCC during a
2-year period, with 700 hospitalizations and 229 clinical
AKI events. Of those with clinical AKI, we estimated
that 25% will have renal non-recovery and 6% will die
within the first 3 months of discharge. Of persons who
develop clinical AKI and survive beyond 3 months post-
discharge, 40% will experience kidney disease progres-
sion during follow-up. Among those without clinical
AKI, 25% will develop kidney disease progression.
For the nested case-cohort approach to evaluate the
association of ambulatory urine biomarkers of kidney in-
jury with hospitalized clinical AKI, we have sufficient
power to detect a hazard ratio of 1.24 per 1-SD differ-
ence in urine biomarker level. For the composite out-
come of renal non-recovery at 3 months and all-cause
mortality post-discharge, there is sufficient power to de-
tect an odds ratio of 1.65 per 1-SD difference in urine
biomarker level. In addition, we have sufficient power to
detect a relative hazard of 1.38 per 1-SD difference in
urine biomarker level for the outcome of kidney disease
progression. When comparing the risk of kidney disease
progression among participants who develop subclinical
AKI to those who do not develop clinical AKI, there is
sufficient power to detect a hazard ratio of 1.26. For the
development and validation of prognostic models, effect
sizes exceeding the estimated minimum detectable ef-
fects are needed for consequential risk stratification [27],
and we will be well-powered to detect the required effect
sizes. Lastly, the number of events for each outcome
relative to the number of candidate predictors is within
recommendations for the development of prediction
models [28].
Discussion
In this paper, we highlighted the need for studies to ad-
dress the excess burden of AKI in the HIV-positive
population. The current model of AKI is incomplete
since it is defined solely based on changes in kidney
function estimates as assessed by serum creatinine. Pre-
vious and current studies of AKI have also frequently
lacked baseline ambulatory measurements of creatinine
levels, leading to AKI misclassifications and biased re-
sults. Most importantly, the current structure of HIV
clinical research studies do not adequately bridge the
ambulatory and inpatient setting. In addition, few studies
addressing AKI have included sufficient numbers of
African Americans despite their heightened risk of AKI
and health consequences. Current methods to measure
urine biomarkers are not feasible for clinical application.
PARIS addresses these key gaps in knowledge and will
advance the progress towards implementation of urine
biomarkers of kidney injury in clinical practice. This
study will serve as an important resource for future
studies of AKI by establishing a repository with both
ambulatory and inpatient biospecimens which are cur-
rently unavailable in existing HIV-positive cohorts. Upon
completion of this study, the resulting predictive model
which will incorporate results from the multiplex HIV-
AKI Risk Panel could be evaluated as a screening tool
for trials comparing management strategies for AKI, and
the Panel could serve as a surrogate endpoint for early
phase AKI therapeutics.
Our study comes with some limitations. First, how
best to define subclinical AKI remains unclear. We will
explore alternative definitions of subclinical AKI and will
evaluate how these definitions correlate with clinical var-
iables and influence our estimates. This approach will
enable us to examine the robustness of our findings and
will inform future research in subclinical AKI. Second,
this is a single center cohort enriched with African
American patients. While we view this as a strength of
the study, the composition of our study population may
ultimately limit the extrapolation of our findings to the
general HIV-positive population. Third, we cannot exter-
nally validate our predictive model due to the lack of
paired ambulatory and inpatient urine samples required
for studying AKI in existing clinical HIV cohorts. To
address some of these limitations, we envision a future
clinical trial to assess the utility of the HIV-AKI
prognostic model compared to standard of care in redu-
cing time to recognition and sequelae of AKI in the
HIV-positive population.
In conclusion, this study will serve as an important re-
source for future studies of AKI by establishing a reposi-
tory with both ambulatory and inpatient biospecimens
that is currently lacking in existing HIV clinical cohorts
and studies of AKI. Upon completion of this study, the
resulting prognostic model which incorporates results
from the multiplex HIV-AKI Risk Panel could be evalu-
ated as a screening tool in trials comparing early manage-
ment of AKI or intensive management after AKI with
current standards of care, and the Panel could serve as a
surrogate endpoint for early phase therapeutic candidates
for AKI.
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